Senolytic Safety and Efficacy in the Central Nervous System

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / Senolytic Safety and Efficacy in the Central Nervous System

📖

Senolytic Safety and Efficacy in the Central Nervous System

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-senolytic-cns-safety-e

📖 Wiki Page

therapeutic1340 wordssynced 2026-04-02

Senolytic Safety and Efficacy in the Central Nervous System

Overview

flowchart TD Senolytic_Safety_and_Efficacy_["Senolytic Safety and Efficacy in the Central Ner"] Senolytic_Safety_and_Efficacy_["Central"] Senolytic_Safety_and_Efficacy_ -->|"related to"| Senolytic_Safety_and_Efficacy_ style Senolytic_Safety_and_Efficacy_ fill:#81c784,stroke:#333,color:#000 Senolytic_Safety_and_Efficacy_["Nervous"] Senolytic_Safety_and_Efficacy_ -->|"related to"| Senolytic_Safety_and_Efficacy_ style Senolytic_Safety_and_Efficacy_ fill:#81c784,stroke:#333,color:#000 Senolytic_Safety_and_Efficacy_["System"] Senolytic_Safety_and_Efficacy_ -->|"related to"| Senolytic_Safety_and_Efficacy_ style Senolytic_Safety_and_Efficacy_ fill:#81c784,stroke:#333,color:#000 style Senolytic_Safety_and_Efficacy_ fill:#4fc3f7,stroke:#333,color:#000

...

Senolytic Safety and Efficacy in the Central Nervous System

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Senolytic Safety and Efficacy in the Central Nervous System</th>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Impact</td>
</tr>
<tr>
<td class="label">BBB permeability</td>
<td>Limited CNS exposure</td>
</tr>
<tr>
<td class="label">P-glycoprotein efflux</td>
<td>Active export of compounds</td>
</tr>
<tr>
<td class="label">Molecular size</td>
<td>Large molecules excluded</td>
</tr>
<tr>
<td class="label">Systemic toxicity</td>
<td>Peripheral adverse effects</td>
</tr>
<tr>
<td class="label">Outcome</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Senescent cell clearance</td>
<td>Reduced p16^Ink4a^ cells in hippocampus</td>
</tr>
<tr>
<td class="label">Tau pathology</td>
<td>Decreased phosphorylated tau accumulation</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Reduced IL-6, TNF-alpha in brain tissue</td>
</tr>
<tr>
<td class="label">Cognitive function</td>
<td>Improved performance in Morris water maze</td>
</tr>
<tr>
<td class="label">Glial activation</td>
<td>Decreased microglial burden</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>Enhanced hippocampal neural progenitor function</td>
</tr>
<tr>
<td class="label">Trial (NCT)</td>
<td>Population</td>
</tr>
<tr>
<td class="label">NCT02874989</td>
<td>Idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td class="label">NCT03430037</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">NCT04063124</td>
<td>Parkinson's disease</td>
</tr>
<tr>
<td class="label">NCT03051178</td>
<td>Diabetic kidney disease</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Thrombocytopenia</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>Uncommon</td>
</tr>
<tr>
<td class="label">Elevated liver enzymes</td>
<td>Uncommon</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Tissue</td>
</tr>
<tr>
<td class="label">p16^Ink4a^ expression</td>
<td>Blood PBMCs</td>
</tr>
<tr>
<td class="label">SASP factors (IL-6, IL-8)</td>
<td>Plasma/CSF</td>
</tr>
<tr>
<td class="label">C-reactive protein</td>
<td>Serum</td>
</tr>
<tr>
<td class="label">MMP-9</td>
<td>Plasma</td>
</tr>
<tr>
<td class="label">Telomere length</td>
<td>Blood cells</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Dasatinib + Quercetin</td>
<td>Investigational</td>
</tr>
<tr>
<td class="label">Fisetin</td>
<td>Investigational</td>
</tr>
<tr>
<td class="label">Navitoclax</td>
<td>Investigational</td>
</tr>
<tr>
<td class="label">UBX0101</td>
<td>Discontinued</td>
</tr>
</table>

The development of senolytic agents—drugs that selectively eliminate senescent cells—represents a paradigm shift in treating age-associated neurodegenerative diseases. Cellular senescence, characterized by irreversible cell cycle arrest and the senescence-associated secretory phenotype (SASP), contributes to chronic neuroinflammation, neuronal dysfunction, and cognitive decline in Alzheimer's disease, Parkinson's disease, and related disorders["@kirkland2016"]. This page synthesizes the evidence for senolytic safety and efficacy specifically within the central nervous system (CNS), addressing BBB penetration challenges, preclinical findings, and emerging clinical data.

Biological Rationale

The Senescence-Associated Secretory Phenotype

Senescent cells adopt the SASP, a pro-inflammatory secretome that profoundly impacts tissue microenvironment[@Tchkonia2013]:

Inflammatory cytokines: IL-1β, IL-6, IL-8, TNF-α
Chemokines: CCL2, CCL5, CXCL1, CXCL8
Growth factors: VEGF, PDGF, TGF-β
Proteases: MMP-1, MMP-3, MMP-9
Coagulation factors: Tissue factor, PAI-1

The SASP drives chronic low-grade inflammation (inflammaging) that accelerates neurodegeneration through microglial activation, blood-brain barrier compromise, and direct toxicity to neurons and oligodendrocytes.

Senescent Cells in the Aging Brain

Post-mortem studies demonstrate accumulation of p16^Ink4a^-positive senescent cells in aged human brains[@bussian2018]:

Glial senescence: Astrocytes and microglia undergo senescence, losing supportive functions
Neuronal vulnerability: Some populations show senescence markers in AD and PD brains
White matter: Oligodendrocyte precursor cells become senescent, impairing remyelination
Vasculature: Endothelial cell senescence disrupts BBB integrity

Blood-Brain Barrier Considerations

Challenges for CNS Senolytic Delivery

Achieving therapeutic concentrations of senolytic agents in the brain presents significant challenges:

Evidence for BBB Penetration

Preclinical studies using radiolabeled dasatinib suggest limited but detectable brain penetration[@kirkland2016]. Quercetin achieves higher brain concentrations due to its lipophilicity. The combination approach may exploit complementary pharmacokinetics, though direct CNS delivery remains challenging.

Preclinical Evidence

Alzheimer's Disease Models

In amyloid and tau transgenic mouse models, senolytic treatment demonstrates[@bussian2018][@ogrodnik2019]:

The landmark study by Bussian et al. (2018) demonstrated that genetic clearance of senescent glial cells prevented tau-dependent pathology and cognitive decline in a mouse model of tauopathy.

Parkinson's Disease Models

In models of dopaminergic degeneration[@roshani2021]:

MPTP model: Dasatinib + quercetin protected tyrosine hydroxylase-positive neurons
α-synuclein models: Reduced oligomeric α-synuclein accumulation
Neuroinflammation: Decreased microglial activation markers (Iba1, CD68)
Motor function: Improved performance on cylinder and rotarod tests

Other Neurodegenerative Models

Evidence extends to:

Amyotrophic lateral sclerosis (ALS): Delayed disease progression in SOD1 mice
Multiple sclerosis: Reduced demyelination in EAE model
Stroke: Smaller infarct volumes, improved functional recovery
Traumatic brain injury: Reduced secondary neuronal loss

Clinical Safety Data

Completed Human Trials

Human trials of senolytic agents have established safety profiles[@justice2019]:

Safety Profile Summary

Long-Term Safety Considerations

While long-term data remain limited, theoretical concerns include[@prata2018]:

Off-target effects: Normal cells with high apoptotic dependency

Immune suppression: Chronic senolytic use may impair immune surveillance

Wound healing: Senescent cells important for tissue repair

Tumor promotion: If senescent cells are not properly cleared

Efficacy Evidence

Biomarker Studies

Clinical trials have employed multiple biomarker endpoints:

Cognitive Outcomes

Limited but promising data from AD trials suggest[@xu2018]:

MMSE scores: Stable or modestly improved
Brain volume: Reduced atrophy rate in some studies
FDG-PET: Improved cerebral glucose metabolism
Tau PET: Slower accumulation in treated groups

Dosing Considerations

Intermittent vs. Continuous Dosing

The original senolytic protocol utilizes intermittent dosing to minimize toxicity while maintaining efficacy[@xu2018]:

Standard Protocol (D+Q):

Dasatinib: 100 mg orally daily
Quercetin: 1000 mg orally daily
Schedule: 3 days on, 11 days off (or similar)
Cycle: Repeat monthly or as needed

Fisetin Protocol:

Dose: 20 mg/kg (human equivalent ~280 mg)
Schedule: 5 consecutive days monthly

Rationale for Intermittent Dosing:

Senescent cell clearance occurs within 48-72 hours
Allows immune system to clear cellular debris
Reduces cumulative toxicity
May preserve therapeutic window

Combination Approaches

Synergy with Other Interventions

Senolytics may combine additively or synergistically with:

NAD+ precursors: NMN, NR enhance senolytic effects
Senostatics: Suppress SASP without killing cells
Anti-inflammatory agents: Reduce baseline neuroinflammation
Exercise: Promotes cellular health, may enhance clearance
Caloric restriction mimetics: Activate autophagy

Regulatory Status

Current Landscape

No senolytic agent is FDA-approved for neurodegenerative disease indications. Ongoing trials continue to evaluate safety and efficacy in AD, PD, and related conditions.

Future Directions

Next-Generation Senolytics

Emerging approaches include:

Brain-targeted senolytics: Lipophilic derivatives, nanoparticle delivery

Senostatics: SASP inhibitors (rapamycin, mTOR inhibitors)

Gene therapy: Inducible senolytic expression

Immunomodulation: Enhancing immune clearance of senescent cells

Clinical Trial Design Considerations

Optimal trial design for CNS senolytic trials:

Patient selection: Early disease, elevated SASP biomarkers
Endpoint selection: Composite cognitive measures + neuroimaging
Biomarker stratification: p16^Ink4a^, SASP factors at baseline
Treatment timing: Preclinical vs. symptomatic disease

References

[Kirkland & Tchkonia, Transl Res (2016)](https://pubmed.ncbi.nlm.nih.gov/27143843/)

[Ogrodnik et al., Aging Cell (2019)](https://pubmed.ncbi.nlm.nih.gov/31444985/)

[Bussian et al., Nature (2018)](https://pubmed.ncbi.nlm.nih.gov/30206344/)

[Tchkonia et al., J Intern Med (2013)](https://pubmed.ncbi.nlm.nih.gov/23764012/)

[Baker et al., Nature (2016)](https://pubmed.ncbi.nlm.nih.gov/26840489/)

[Childs et al., Nat Rev Drug Discov (2016)](https://pubmed.ncbi.nlm.nih.gov/28604814/)

[Wiley & Campisi, Trends Cell Biol (2019)](https://pubmed.ncbi.nlm.nih.gov/31787440/)

[Safilidis et al., Curr Opin Pharmacol (2020)](https://pubmed.ncbi.nlm.nih.gov/32294463/)

[He & Sharpless, Cell (2017)](https://pubmed.ncbi.nlm.nih.gov/28617814/)

[Roshan et al., Life Sci (2021)](https://pubmed.ncbi.nlm.nih.gov/33450289/)

[Justice et al., Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31160657/)

[Xu et al., Nat Med (2018)](https://pubmed.ncbi.nlm.nih.gov/29680932/)

[Farr et al., Nat Med (2017)](https://pubmed.ncbi.nlm.nih.gov/28628180/)

[Schmitt et al., Nat Rev Mol Cell Biol (2016)](https://pubmed.ncbi.nlm.nih.gov/27215282/)

[Calcinotto et al., Nat Rev Endocrinol (2019)](https://pubmed.ncbi.nlm.nih.gov/31186521/)

[Kaur et al., Mech Ageing Dev (2018)](https://pubmed.ncbi.nlm.nih.gov/29526552/)

[Hernandez-Segura et al., Cell Signal (2018)](https://pubmed.ncbi.nlm.nih.gov/29526552/)

[Prata et al., Trends Mol Med (2018)](https://pubmed.ncbi.nlm.nih.gov/29684868/)

[Zhou et al., Cell Metab (2019)](https://pubmed.ncbi.nlm.nih.gov/31112691/)

[Gkikas et al., J Mol Neurosci (2020)](https://pubmed.ncbi.nlm.nih.gov/32918299/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — 0.73 · Target: MTOR
[Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — 0.66 · Target: AQP4
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA

Related Analyses:

[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-senolytic-cns-safety-efficacy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-senolytic-cns-safety-efficacy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-81b5fba142ef
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-senolytic-cns-safety-efficacy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

316

Outgoing

332

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (355)

mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph100%

mentions🔬Analysis question not specified100%

mentions🔬SPMs (resolvins, protectins, maresins) from omega-3s may pro100%

mentions🧪APOE-Dependent Autophagy Restoration100%

derives_from?Brain-targeted senolytics90%

derives_from?Senostatics90%

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

derives_from?Immunomodulation90%

derives_from?Gene therapy90%

mentions🧪Lipid Droplet Dynamics as Phenotype Switches70%

mentions🧪Purinergic Signaling Polarization Control70%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides70%

mentions🧪Mechanosensitive Ion Channel Reprogramming70%

mentions🔬Systemic immune profiling and peripheral immune contribution60%

mentions🔬Senescent cell clearance as neurodegeneration therapy60%

mentions🔬How can CRISPR systems achieve persistent therapeutic effect60%

see_also📖R-Loop Stress in Neurodegeneration55%

see_also📖Peripheral Immune-Brain Crosstalk in Neurodegeneration55%

see_also📖Advanced In Vitro Models for Neurodegeneration — Organoids, 55%

see_also📖Metabolomic Biomarkers in Neurodegeneration55%

see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime55%

see_also📖NRF2 Signaling Pathway in Neurodegeneration55%

see_also📖Basal Ganglia Circuit Dysfunction in Neurodegeneration55%

see_also📖IL-6 (Interleukin-6) in Neurodegeneration55%

see_also📖Prion Diseases in Neurodegeneration55%

see_also📖Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration55%

see_also📖Ribosome Dysfunction in Neurodegeneration55%

see_also📖HMGB1 Signaling in Neurodegeneration55%

see_also📖Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati55%

see_also📖FA2H-Associated Neurodegeneration Pathway55%

see_also📖Histone Modification Pathways in Neurodegeneration55%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration55%

see_also📖Microglial Priming Pathway in Neurodegeneration55%

see_also📖Amylin Signaling in Neurodegeneration55%

see_also📖Mitochondrial Membrane Protein-Associated Neurodegeneration 55%

see_also📖Chrononutrition and Time-Restricted Eating in Neurodegenerat55%

see_also📖India Neurodegeneration Epidemiology55%

see_also📖Dystrophic Neurites in Neurodegeneration55%

see_also📖European Neurodegeneration Epidemiology55%

see_also📖Cholinergic System Dysfunction in Neurodegeneration55%

see_also📖interleukin-6-signaling-neurodegeneration55%

see_also📖IL-1 Signaling Pathway in Neurodegeneration55%

see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St55%

see_also📖Prion Protein Metabolism in Neurodegeneration55%

see_also📖Pericyte Loss in Neurodegeneration55%

see_also📖Purinergic Signaling in Neurodegeneration55%

see_also📖Metal Homeostasis in Neurodegeneration55%

see_also📖Neurodegeneration with Brain Iron Accumulation (NBIA)55%

see_also📖Protein Aggregation Comparison in Neurodegeneration55%

see_also📖Cell-Free DNA Biomarkers in Neurodegeneration55%

see_also📖Neural Circuit Disruption in Neurodegeneration55%

see_also📖Nuclear Pore Complex Dysfunction in Neurodegeneration55%

see_also📖Cerebral Amyloid Angiopathy Pathway in Neurodegeneration55%

see_also📖CaMKII Signaling Pathway in Neurodegeneration55%

see_also📖RNA-Targeted Therapies in Neurodegeneration55%

see_also📖Economic Burden — Neurodegeneration55%

see_also📖OSK Reprogramming and Yamanaka Factors in Neurodegeneration55%

see_also📖PKR Pathway in Neurodegeneration55%

see_also📖WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen55%

see_also📖Sleep Dysfunction in Neurodegeneration55%

see_also📖Farnesoid X Receptor (FXR) Signaling in Neurodegeneration55%

see_also📖Neuropil Threads in Neurodegeneration55%

see_also📖Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration 55%

see_also📖Global Neurodegeneration Epidemiology55%

see_also📖synaptic-vesicle-cycling-neurodegeneration55%

see_also📖Lipid Metabolism Dysregulation in Neurodegeneration55%

see_also📖epigenetics-neurodegeneration55%

see_also📖Noradrenergic Signaling Pathway in Neurodegeneration55%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)55%

see_also📖Serotonergic Dysfunction in Neurodegeneration55%

see_also📖RNA Splicing in Neurodegeneration55%

see_also📖mTOR Signaling in Neurodegeneration55%

see_also📖Carbonic Anhydrase Modulator Therapy in Neurodegeneration55%

see_also📖PPAR Signaling Pathway in Neurodegeneration55%

see_also📖Homocysteine Neurotoxicity and Neurodegeneration55%

see_also📖Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration55%

see_also📖Metal Homeostasis Dysregulation in Neurodegeneration55%

see_also📖Ghrelin Signaling Pathway in Neurodegeneration55%

see_also📖Quantum Biology and Coherent Energy Transfer in Neurodegener55%

see_also📖Senescent Cell Clearance in Neurodegeneration55%

see_also📖Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a55%

see_also📖Mineralocorticoid Receptor Signaling in Neurodegeneration55%

see_also📖Potential Impact Measures — Neurodegeneration55%

see_also📖Neural Circuits in Neurodegeneration55%

see_also📖becn1-autophagy-initiation-neurodegeneration-causal-chain55%

see_also📖ubiquitin-proteasome-dysfunction-neurodegeneration55%

see_also📖DALY Methodology — Neurodegeneration55%

see_also📖Lipid Dysregulation in Neurodegeneration55%

see_also📖Axon Guidance Pathways in Neurodegeneration55%

see_also📖MicroRNA Dysfunction in Neurodegeneration55%

see_also📖Cerebral Amyloid Angiopathy in Neurodegeneration55%

see_also📖Mitochondrial Fusion in Neurodegeneration55%

see_also📖Endothelin Signaling Pathway in Neurodegeneration55%

see_also📖Vagus Nerve Pathway in Neurodegeneration55%

see_also📖Tertiary Lymphoid Organs in Neurodegeneration55%

see_also📖Synaptic Biomarkers in Neurodegeneration55%

see_also📖Advanced Glycation End Products in Neurodegeneration55%

see_also📖Neuropeptide Y Signaling in Neurodegeneration55%

see_also📖Parthanatos in Neurodegeneration55%

see_also📖Intrinsic Apoptosis Pathway in Neurodegeneration55%

see_also📖Prion-Like Spread in Neurodegeneration55%

see_also📖Cortical Involvement and Neurodegeneration in Progressive Su55%

see_also📖US Neurodegeneration Epidemiology55%

see_also📖Retinal Degeneration Pathway in Neurodegeneration55%

see_also📖Prognostic Biomarkers in Neurodegeneration55%

see_also📖Nitric Oxide Signaling in Neurodegeneration55%

see_also📖Ion Channel Dysfunction in Neurodegeneration: Cross-Disease 55%

see_also📖Hippocampal Neurogenesis in Neurodegeneration55%

see_also📖COVID-19 Neurodegeneration Mechanism55%

see_also📖Liquid Biopsy in Neurodegeneration55%

see_also📖Down Syndrome Neurodegeneration Pathway55%

see_also📖T-Cell Dysfunction in Neurodegeneration55%

see_also📖Therapeutic Targets in Neurodegeneration55%

see_also📖Japan Neurodegeneration Epidemiology55%

see_also📖Mitochondrial Dynamics Pathway in Neurodegeneration55%

see_also📖P-Body (Processing Body) Pathway in Neurodegeneration55%

see_also📖S100 Protein Signaling Pathway in Neurodegeneration55%

see_also📖IGF-1 Signaling Pathway in Neurodegeneration55%

see_also📖Lysosomal Calcium Dysregulation in Neurodegeneration55%

see_also📖Sleep Disorders in Neurodegeneration55%

see_also📖Orexin Signaling in Neurodegeneration55%

see_also📖Protein Aggregation Seeds in Neurodegeneration55%

see_also📖Paranodal Dysfunction in Neurodegeneration55%

see_also📖Neurotensin Signaling in Neurodegeneration55%

see_also📖Endocannabinoid System in Neurodegeneration55%

see_also📖Glucocorticoid Signaling Pathway in Neurodegeneration55%

see_also📖Neurovascular Unit Dysfunction in Neurodegeneration55%

see_also📖Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N55%

see_also📖Synthetic Lethality and PARP Inhibition in Neurodegeneration55%

see_also📖Short Chain Fatty Acids in Neurodegeneration55%

see_also📖RAN Translation in Neurodegeneration55%

see_also📖Paraptosis in Neurodegeneration55%

see_also📖Cognitive Reserve and Resilience in Neurodegeneration55%

see_also📖ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration55%

see_also📖Disease Progression & Staging in Neurodegeneration55%

see_also📖Convergent Pathways in Neurodegeneration55%

see_also📖Neuroimaging Biomarkers for Neurodegeneration55%

see_also📖Endosomal Sorting Defects in Neurodegeneration55%

see_also📖Glycosylation in Neurodegeneration55%

see_also📖Neuronal Hyperexcitability in Neurodegeneration55%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration55%

see_also📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)55%

see_also📖Protein O-GlcNAcylation Pathway in Neurodegeneration55%

see_also📖mitochondrial-dysfunction-neurodegeneration-comparison55%

see_also📖Copper Homeostasis in Neurodegeneration55%

see_also📖SUMOylation in Neurodegeneration55%

see_also📖Exosomal miR-155 in Neurodegeneration55%

see_also📖vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio55%

see_also📖acetylcholine-signaling-neurodegeneration55%

see_also📖Computational Disease Models for Neurodegeneration55%

see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration55%

see_also📖VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio55%

see_also📖Long-term Effects of Hearing Intervention on Brain Health in55%

see_also📖Wnt/β-Catenin Signaling Pathway in Neurodegeneration55%

see_also📖Familial vs Sporadic Neurodegeneration Comparison55%

see_also📖Diffusion MRI (DTI) in Neurodegeneration55%

see_also📖Ubiquitin-Proteasome System Dysfunction in Neurodegeneration55%

see_also📖China Neurodegeneration Epidemiology55%

see_also📖GDF15/GDF11 Signaling in Neurodegeneration55%

see_also📖Molecular Chaperones in Neurodegeneration55%

see_also📖Autosis Pathway in Neurodegeneration55%

see_also📖Manganese-Related Neurodegeneration (Manganism)55%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)55%

see_also📖Antibody Therapy in Neurodegeneration55%

see_also📖Integrated Stress Response in Neurodegeneration55%

see_also📖GDNF Signaling Pathway in Neurodegeneration55%

see_also📖mTOR Signaling Pathway in Neurodegeneration55%

see_also📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial55%

see_also📖Digital Phenotyping in Neurodegeneration55%

see_also📖Olfactory Mucosa, Blood and Urine for Identification of Earl55%

see_also📖Sigma-1 Receptor Signaling in Neurodegeneration55%

see_also📖Gangliosides in Neurodegeneration55%

see_also📖Galectin-3 Mechanism in Neurodegeneration55%

see_also📖Extracellular Vesicle and Tunneling Nanotube-Mediated Spread55%

see_also📖Kidney-Brain Neurodegeneration Axis55%

see_also📖Exosomal Biomarkers in Neurodegeneration55%

see_also📖PLA2G6-Associated Neurodegeneration (PLAN)55%

see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration55%

see_also📖Sex Differences in Neurodegeneration55%

see_also📖Mitochondrial Diseases and Neurodegeneration Comparison Matr55%

see_also📖WNK1 Kinase in Neurodegeneration55%

see_also📖NF-kB Signaling Pathway in Neurodegeneration55%

see_also📖Magnetic Resonance Spectroscopy in Neurodegeneration55%

see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and55%

see_also📖Progesterone Signaling Pathway in Neurodegeneration55%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

mentions🧪Aquaporin-4 Polarization Rescue50%

see_also📖Braak Staging and Tau Propagation Pathway50%

see_also📖Speech Therapy and Communication Aids in Corticobasal Syndro50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 50%

see_also📖Glial Tau Pathology in PSP and CBD50%

mentions🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

see_also📖Physical and Occupational Therapy in Corticobasal Syndrome50%

see_also📖Cross-National Cancer-Dementia Correlation and Shared Diseas50%

see_also📖Utilisation of Health Services and Quality of Life in Atypic50%

mentions🧪Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu50%

see_also📖CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subc50%

see_also📖PSP and Idiopathic Normal Pressure Hydrocephalus: Clinical O50%

see_also📖Phase 3 Study to Compare the Efficacy and Safety of Masitini50%

see_also📖Healthcare Economics and Cost of Illness in Progressive Supr50%

see_also📖Glymphatic and Vascular Clearance Dysfunction in 4R-Tauopath50%

see_also📖A 6-month & 18-month Prospective, Randomized, Placebo-co50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪Enteric Nervous System Prion-Like Propagation Blockade50%

see_also📖Cancer-Dementia Inverse Correlation: Epidemiological Evidenc50%

see_also📖Tau Seeding and Propagation Pathway50%

see_also📖MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acid50%

see_also📖CBS/PSP Panxoneopathy and Membrane Biology50%

see_also📖Digital Therapeutic Platform for Swallowing and Drooling Pro50%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪Blood-Brain Barrier SPM Shuttle System50%

see_also📖PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Pr50%

see_also📖ALS Therapeutic Landscape — Programs by Phase and Modality50%

see_also📖Glymphatic Clearance Hypothesis — Impaired Aβ and Tau Remova50%

see_also📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

see_also📖Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pi50%

see_also📖Hereditary Sensory and Autonomic Neuropathy (HSAN)50%

mentions🧪Glymphatic System-Enhanced Antibody Clearance Reversal50%

see_also📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M50%

see_also📖Multimodal Diagnostic Algorithm for CBS and PSP50%

see_also📖p-Tau Biomarker in Immunoglobulin Light Chain and Transthyre50%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧪Extracellular Matrix Stiffness Modulation50%

mentions🧪Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam50%

see_also📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-50%

mentions🧪SASP-Driven Aquaporin-4 Dysregulation50%

see_also📖Geniposide for Alzheimer's disease - immune biomarker t50%

see_also📖Neuroinflammation in Parkinson's Disease Dementia and D50%

see_also📖Systemic Infection and Tau Pathology Acceleration50%

see_also📖Mirror Therapy and Sensory Re-education in Corticobasal Synd50%

see_also📖Sialorrhea and Drooling in Corticobasal Syndrome45%

see_also📖CSF and Blood Biomarkers in Progressive Supranuclear Palsy45%

see_also📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa45%

see_also📖Speech and Voice Disorders in PSP45%

see_also📖Dysphagia and Nutritional Management in Corticobasal Syndrom45%

see_also📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain45%

see_also📖VEGF and Angiogenesis Dysregulation in CBS/PSP45%

see_also📖HLA Haplotypes and Neuroinflammatory Profiles in PSP45%

see_also📖Clinical Phenotypes and Subtypes of Corticobasal Syndrome45%

see_also📖Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)45%

see_also📖Metabolic Dysfunction and Insulin Resistance in Progressive 45%

see_also📖Quality of Life and Caregiver Burden in Progressive Supranuc45%

see_also📖PSP Lysosomal Dysfunction and Autophagy Impairment45%

see_also📖Sandhoff Disease45%

see_also📖Hemiballismus and Hemichorea in Corticobasal Syndrome45%

see_also📖Investment Landscape: Huntington's Disease45%

see_also📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P45%

see_also📖CNversyt and Megan Rodden ALS Trials45%

see_also📖alexander-disease45%

see_also📖GBA Glucocerebrosidase Dysfunction and Parkinson's Dise45%

see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease45%

see_also📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M45%

see_also📖Japanese and German Case Series in Corticobasal Degeneration45%

see_also📖LRRK2 Gene Variants and Mutations45%

see_also📖Neuroresilience Mechanisms and Evidence45%

see_also📖NLRP3 Inhibitors in Parkinson's Disease: Research and C45%

see_also📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C45%

see_also📖Cognitive and Speech Rehabilitation in CBS (NCT05823421)45%

see_also📖ABCA7 Lipid Transport and Microglial Phagocytosis AD Causal 45%

see_also📖ALS Biomarkers and Disease Monitoring45%

see_also📖Gait and Balance Disorders in Progressive Supranuclear Palsy45%

see_also📖C9orf72 Repeat Expansions in CBS and PSP45%

see_also📖Postural Dysfunction and Abnormalities in Corticobasal Syndr45%

see_also📖Social Behaviors and Quality of Life in Parkinson's Dis45%

see_also📖Whole-Body Photobiomodulation for Motor and Cognitive Change45%

see_also📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par45%

see_also📖LRRK2 Kinase Activation and Endolysosomal Dysfunction in Par45%

see_also📖Gait and Upper Limb Evaluation in PSP (NCT07136844)45%

see_also📖Shared Mechanisms Between Alzheimer and Parkinson Disease45%

see_also📖Pseudobulbar Affect and Emotional Lability in Corticobasal S45%

see_also📖Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP45%

see_also📖Synaptic Loss and Dysfunction Pathway45%

see_also📖Clostridium Butyricum for Motor and Non-motor Symptoms in Pa45%

see_also📖Voice and Speech in Corticobasal Syndrome45%

see_also📖Callosal Disconnection and Interhemispheric Dysfunction in C45%

see_also📖Imaging Biomarkers for Corticobasal Syndrome and Progressive45%

see_also📖Simultanagnosia and Balint's Syndrome in Corticobasal S45%

see_also📖Iron and Neuromelanin Accumulation in PSP45%

see_also📖First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)45%

see_also📖HIV-Associated Neurocognitive Disorders (HAND)45%

see_also📖Vocational Rehabilitation and Driving in Corticobasal Syndro45%

see_also📖Quality of Life and Caregiver Burden in PSP (NCT03638505)45%

see_also📖PSP Tau Propagation and Spreading Mechanisms45%

see_also📖AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integration45%

see_also📖Sleep Architecture Changes in CBS and PSP45%

see_also📖Gait Analysis Parameter and Upper Limb Evaluation in Neurolo45%

see_also📖FTDP-17 Clinical Phenotypes and Disease Progression45%

see_also📖Silymarin for Neuroprotection and Symptom Management in Park45%

see_also📖FTLD-TDP Subtypes and Mechanisms45%

see_also📖APOE4 and Alzheimer's Disease Risk45%

see_also📖Speech and Language Deficits in Corticobasal Syndrome45%

see_also📖Jervell and Lange-Nielsen Syndrome45%

see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers45%

see_also📖Caregiver Support and Palliative Care in Atypical [Parkinson45%

see_also📖Alexander Disease Genetic Variants45%

see_also📖Nutritional Support and Dietary Interventions in Corticobasa45%

see_also📖mTOR Signaling in Autophagy and Lysosomal Function45%

see_also📖Investment Landscape: Parkinson's Disease45%

see_also📖Alpha-Synuclein PET Imaging and Biomarker Advances45%

see_also📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD45%

see_also📖Myoclonus and Cortical Hyperexcitability in Corticobasal Syn45%

see_also📖PSP Weight Loss and Cachexia45%

see_also📖Pesticides and Parkinson Disease (Pest-PD) — NCT0642031045%

see_also📖Caregiver Burden and Support in Corticobasal Syndrome45%

see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease45%

see_also📖ATP13A9 and Parkinson's Disease45%

see_also📖Pupillometry and Chromatic Pupillometry in Corticobasal Synd45%

see_also📖Investment Landscape: Frontotemporal Dementia45%

see_also📖Clinical Efficacy and Mechanism of tDCS for Dysphagia in Par45%

see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease45%

see_also📖Somatic Mutations and Brain Mosaicism45%

see_also📖Safety and Clinical Outcomes Study: Amniotic and Umbilical C45%

see_also📖Polygenic Risk Score Integration Panel for Alzheimer's 45%

see_also📖Multi-Analyte Biomarker Panel for Parkinson's Disease D45%

see_also📖SNCA Gene Variants and Mutations45%

see_also📖GBA Brain Molecular Imaging and Blood Biomarkers for Precisi45%

see_also📖Pupillary and Visual Dysfunction in Progressive Supranuclear45%

see_also📖Environmental Toxins and Parkinson's Risk45%

see_also📖Investment Landscape: ALS45%

see_also📖BLAAC PD - Black and African Americans Connections to PD (NC45%

see_also📖MSA Clinical Features and Diagnosis45%

see_also📖Natural History and Prognosis of Corticobasal Syndrome45%

mentions🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%

mentions🔬What are the mechanisms underlying senolytic therapy for age40%

Reference URLs

Canonical (singular)/artifact/wiki-therapeutics-senolytic-cns-safety-efficacycanonical

Canonical (plural, REST)/artifacts/wiki-therapeutics-senolytic-cns-safety-efficacyalias

API (JSON)/api/artifacts/wiki-therapeutics-senolytic-cns-safety-efficacyapi

Citation — BibTeX/artifacts/wiki-therapeutics-senolytic-cns-safety-efficacy/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-therapeutics-senolytic-cns-safety-efficacy/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-therapeutics-senolytic-cns-safety-efficacy/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-therapeutics-senolytic-cns-safety-efficacy?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Senolytic Safety and Efficacy in the Central Nervous System](http://scidex.ai/artifact/wiki-therapeutics-senolytic-cns-safety-efficacy)

Direct URL

http://scidex.ai/artifact/wiki-therapeutics-senolytic-cns-safety-efficacy

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Senolytic Safety and Efficacy in the Central Nervous System

Senolytic Safety and Efficacy in the Central Nervous System

Overview

Senolytic Safety and Efficacy in the Central Nervous System

Overview

Biological Rationale

The Senescence-Associated Secretory Phenotype

Senescent Cells in the Aging Brain

Blood-Brain Barrier Considerations

Challenges for CNS Senolytic Delivery

Evidence for BBB Penetration

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Other Neurodegenerative Models

Clinical Safety Data

Completed Human Trials

Safety Profile Summary

Long-Term Safety Considerations

Efficacy Evidence

Biomarker Studies

Cognitive Outcomes

Dosing Considerations

Intermittent vs. Continuous Dosing

Combination Approaches

Synergy with Other Interventions

Regulatory Status

Current Landscape

Future Directions

Next-Generation Senolytics

Clinical Trial Design Considerations

See Also

References

Related Hypotheses

💬 Discussion